Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort

Vavricka, Stephan R.; Rogler, Gerhard; Gantenbein, Claudine; Spoerri, Muriel; Vavricka, Mareike Prinz; Navarini, Alexander A.; French, Lars E.; Safroneeva, Ekaterina; Fournier, Nicolas; Straumann, Alex; Froehlich, Florian; Fried, Michael; Michetti, Pierre; Seibold, Frank; Lakatos, László; Peyrin–Biroulet, Laurent; Schoepfer, Alain

doi:10.1097/mib.0000000000000429

Cited by 190 publications

(154 citation statements)

References 29 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…While TNFi therapies have a direct effect on inflammation in the joints, extra-intestinal manifestations (EIM) are thought to be driven by gut inflammation [17]. Thus, the therapy most effective for the bowels will likewise have an impact on joint symptoms.…”

Section: Discussionmentioning

confidence: 99%

The Association Between Arthralgia and Vedolizumab Using Natural Language Processing

Cai

Lin

Bond

et al. 2018

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background: The gut-selective nature of vedolizumab has raised questions regarding increased joint pain or arthralgias with its use in IBD patients. Since arthralgias are seldom coded and thus difficult to study, few studies have examined the comparative risk of arthralgias between vedolizumab and tumor necrosis factor inhibitor (TNFi). Objectives: To evaluate the application of natural language processing (NLP) to identify arthralgias in the clinical notes, and to compare the risk of arthralgia between vedolizumab and TNFi in IBD. Methods: We performed a retrospective study using a validated electronic medical record (EMR) based IBD cohort from 2 large tertiary care centers. The index date was the first date of vedolizumab or TNFi prescription. Baseline covariates were assessed 1-year period before the index date; patients were followed 1-year after the index date. The primary outcome was arthralgias defined using NLP. Using inverse probability of treatment weight to balance the cohorts, we then constructed Cox regression models to calculate the hazard ratio (HR) for arthralgia in the vedolizumab vs TNFi groups. Results: We studied 367 patients on vedolizumab and 1,218 on TNFi IBD patients. Patients on vedolizumab were older, mean age 41.2 vs. 34.9 years, and had more prevalent use of immunomodulators, 52.3% vs. 31.9%, than TNFi users. Our data did not observe a significant increased risk of arthralgias in the vedolizumab group compared with TNFi (HR, 1.20; 95%CI, 0.97–1.49). Conclusions: In this large observational study, we did not find a significant increased risk of arthralgias associated with vedolizumab use compared with TNFi.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association Between Arthralgia and Vedolizumab Using Natural Language Processing

Cai

Lin

Bond

et al. 2018

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…A recent study indicates that the prevalence of PSC is higher when MR cholangiography is used for screening of patients with IBD . Approximately, 70%‐80% of patients with PSC are diagnosed with IBD as well, the majority with UC, and 25% of PSC‐IBD patients are diagnosed with PSC before IBD . PSC may progress to hepatic cirrhosis and end‐stage liver disease, and as no effective medical therapies exist, liver transplantation might be indicated …”

Section: Introductionmentioning

confidence: 99%

“…6 Approximately, 70%-80% of patients with PSC are diagnosed with IBD as well, the majority with UC, 4 and 25% of PSC-IBD patients are diagnosed with PSC before IBD. 7,8 PSC may progress to hepatic cirrhosis and end-stage liver disease, and as no effective medical therapies exist, liver transplantation might be indicated. 4 The subgroup of IBD patients with concomitant PSC has been described as a distinct IBD phenotype with high prevalence of pancolitis in UC or colitis in CD, 9,10 and higher risk of pouch dysfunction or acute pouchitis.…”

mentioning

confidence: 99%

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

Sørensen

Nielsen

Andersson

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

“…This ulceration usually occurs with increased intestinal disease activity [20,21]. Approximately 10-30% of patients with IBD have oral mucosal ulcers, and the oral manifestation occasionally precedes intestinal symptoms [22][23][24]. In general, oral ulcers are more common in Crohn's disease compared to ulcerative colitis, and more prevalent in children compared to adults [25].…”

Section: Inflammatory Bowel Diseasesmentioning

confidence: 99%

Recurrent Aphthous Stomatitis – a Reflection of Gastrointestinal Diseases?

Lewkowicz¹

2015

Dent. Med. Probl.

View full text Add to dashboard Cite

Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort

Cited by 190 publications

References 29 publications

The Association Between Arthralgia and Vedolizumab Using Natural Language Processing

The Association Between Arthralgia and Vedolizumab Using Natural Language Processing

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

Recurrent Aphthous Stomatitis – a Reflection of Gastrointestinal Diseases?

Contact Info

Product

Resources

About